Quick Answer
Outlook Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $8.08 million for the year ending 2025.
- Outlook Therapeutics, Inc. showed a decrease of -45.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Outlook Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on December 19, 2025.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $425.8 thousand | Q2 2015: $5.38 million | Q4 2015: $5.58 million | Q1 2016: $2.84 million | Q2 2016: $13.56 million | Q4 2016: $2.08 million | Q1 2017: $81.0 thousand | Q2 2017: $139.9 thousand | Q3 2017: $3.19 million | Q4 2017: $13.84 million | Q1 2018: $5.94 million | Q2 2018: $11.80 million | Q4 2018: $227.7 thousand | Q1 2019: $155.5 thousand | Q2 2019: $14.03 million | Q4 2019: $1.33 million | Q1 2020: $4.65 million | Q2 2020: $23.95 million | Q4 2020: $5.57 million | Q1 2021: $37.17 million | Q2 2021: $19.69 million | Q4 2021: $70.15 million | Q1 2022: $58.42 million | Q2 2022: $26.02 million | Q4 2022: $52.34 million | Q1 2023: $43.63 million | Q2 2023: $33.71 million | Q4 2023: $10.36 million | Q1 2024: $47.23 million | Q2 2024: $32.02 million | Q4 2024: $5.70 million | Q1 2025: $7.56 million | Q2 2025: $8.90 million | Q3 2025: $8.08 million | Q4 2025: $8.68 million.
- Over the full 12 years of available data (2014 to 2025), Outlook Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 244.1%.
- Historical annual values: Fiscal year 2025: $8.08 million | Fiscal year 2024: $14.93 million | Fiscal year 2023: $23.39 million | Fiscal year 2022: $17.40 million | Fiscal year 2021: $14.48 million | Fiscal year 2020: $12.54 million | Fiscal year 2019: $8.02 million | Fiscal year 2018: $1.72 million | Fiscal year 2017: $3.19 million | Fiscal year 2016: $2.35 million | Fiscal year 2015: $9.07 million | Fiscal year 2014: $2.35 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: